ICER to Perform Value-Assessment for KarXT Schizophrenia Treatment

July 5th, 2023|Categories: Featured, HEOR Feature, Industry News|Tags: , , , , , |

The Institute for Clinical and Economic Review (ICER) will perform a value-assessment on KarXT (xanomeline tartrate/trospium chloride), Karuna Therapeutics’ experimental therapeutic for schizophrenia. Public discussion of the assessment will take place next February at the 2024 New England CEPAC meeting.

Go to Top